Form 4: Arcturus Therapeutics Director Acquires Stock Options

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted stock options for 15,000 shares.

Summary

• Moncef Slaoui, a Director at Arcturus Therapeutics Holdings Inc., was granted stock options.
• The options are for 15,000 shares of common stock.
• The exercise price for these options is $7.30 per share.
• The options vest monthly over a one-year period from the grant date.
• This grant represents the 2026 annual grant to Mr. Slaoui as a member of the Board of Directors.
• The earliest transaction date reported is June 5, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard director compensation and does not contain new operational or financial performance data.

Positives

• Director compensation through stock options aligns management interests with shareholders.
• The grant of options suggests continued confidence in the company's future prospects by the board.
• The vesting schedule over one year encourages long-term commitment from the director.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• Potential dilution to existing shareholders if a significant number of options are exercised.

Future Outlook

The grant of stock options with an exercise price of $7.30 and a 10-year expiration suggests a positive long-term outlook for the company's stock price, as the options will only be valuable if the stock price exceeds this level.

Management Comments

• This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Industry Context

StockSavvy.ai notes that grants of stock options to directors are a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize leadership and align their financial interests with the long-term success of the company, especially given the inherent volatility and long development cycles in this industry.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns director incentives with shareholder value creation.
• Employees: Standard compensation practice for directors, not directly impacting most employees.
• Management: Reinforces the compensation structure for board members.

Next Steps

• Monthly vesting of stock options over a one-year period.
• Potential exercise of stock options if the stock price exceeds $7.30 before June 5, 2036.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Form 4, Stock Options, Director Grant, Beneficial Ownership, SEC Filing, Executive Compensation